Add BrightSurf on Google Email

Exercise helps patients with advanced breast cancer, especially if they are suffering with pain

A randomized controlled trial found that exercise programmes reduced fatigue and improved quality of life for patients with metastatic breast cancer. The study showed the greatest benefit among younger patients, but also suggested that supervised exercise can be beneficial for all patients with advanced disease.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateMar 19, 2024

Attacking metastatic prostate cancer early with combination treatment approach improves outcomes in preliminary study

A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.

AI may predict spread of lung cancer to brain

A new study uses AI to predict whether early-stage lung cancer will spread to the brain, allowing for more targeted and effective treatment. The algorithm achieved an accuracy rate of 87%, outperforming human pathologists in some cases.

SourceWashU Medicine·JournalThe Journal of Pathology·TypeImaging analysis·DateMar 11, 2024

Radioguided surgery accurately detects and removes metastatic lymph nodes in newly diagnosed prostate cancer patients

New research reveals that radioguided surgery can effectively detect and remove metastatic pelvic lymph nodes in newly diagnosed prostate cancer patients. The procedure targets the prostate-specific membrane antigen, improving nodal staging to guide treatment recommendations.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateMar 5, 2024

UCLA-led research results in FDA approval of 4-drug combination for frontline treatment of metastatic pancreatic cancer

A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.

New therapeutic strategy for metastatic prostate cancer patients resistant to standard treatment

Researchers at Germans Trias i Pujol Research Institute have identified a combination of drugs that could change the treatment of patients with prostate cancer resistant to docetaxel. The study proposes a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel.

SourceGermans Trias i Pujol Research Institute·JournalFrontiers in Pharmacology·TypeExperimental study·DateFeb 2, 2024

Novel approach for lymph node metastasis treatment

Researchers at Tohoku University developed a novel approach for treating lymph node metastasis by administering anticancer drugs directly into the LNs, improving efficacy and reducing side effects. The Lymphatic Drug Delivery System (LDDS) targets sentinel lymph nodes, generating antitumor effects locally.

SourceTohoku University·JournalBiomedicine & Pharmacotherapy·DateJan 12, 2024

Risk model based on routine blood work predicts treatment response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

A risk model based on routine blood work can identify cancer patients who are more likely to benefit from immune checkpoint inhibitors, increasing treatment efficacy and cost-effectiveness. The study found that patients in the low-risk group had a higher response rate and longer overall survival compared to those in the high-risk group.

SourceUniversity of Eastern Finland·JournalBMC Cancer·DateJan 3, 2024

Role of enzyme SMYD3 clarified in prostate cancer progression

Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available

SourceUniversity of Maryland Baltimore County·JournalScience Advances·TypeExperimental study·DateDec 21, 2023

Researchers uncover on/off switch for breast cancer metastasis

A Stanford University study reveals that ENPP1 is produced by both cancer cells and healthy cells around tumors, with high levels linked to immunotherapy resistance and metastases. Researchers found that targeting ENPP1 could improve patient responses to existing medicines and help clinicians better predict patient outcomes

SourceStanford University·JournalProceedings of the National Academy of Sciences·DateDec 20, 2023

Seeing cancer’s spread through a computational window

Researchers at Duke University have developed a new computational model called Adaptive Physics Refinement (APR) that can simulate the movement of individual cancer cells across long distances within the entire human body. This approach captures detailed cellular interactions and their effects on cellular trajectory, providing valuable...

SourceDuke University·TypeExperimental study·DateNov 27, 2023

New drug developed for melanoma and lung cancer shows potential in treatment of cutaneous squamous cell carcinoma – the most common metastatic skin cancer

A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.

SourceUniversity of Turku·JournalOncogene·DateNov 22, 2023

Immunotherapy drug is well tolerated in lung cancer patients with limited physical function, study suggests

A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.

SourceUniversity of Pittsburgh·JournalEClinicalMedicine·TypeRandomized controlled/clinical trial·DateNov 21, 2023

Researchers decipher the mechanism by which the MAF protein promotes breast cancer metastasis

Researchers at IRB Barcelona have identified the mechanism by which the MAF protein promotes breast cancer metastasis, revealing a key interaction with the estrogen receptor. This finding opens up new therapeutic options for patients with high MAF levels, who may benefit from treatments aimed at preventing metastases.

Immune checkpoint inhibition, when administered together with single fraction stereotactic radiosurgery, does not appear to increase risk of radiation necrosis in patients with brain metastases

A multi-institutional study found that immune checkpoint inhibition and single fraction stereotactic radiosurgery does not increase the risk of radiation necrosis in patients with brain metastases from non-small cell lung cancer. The study suggests that treatment with immune checkpoint inhibitors can continue when radiation necrosis oc...

SourceBaptist Health South Florida·JournalJournal of Neuro-Oncology·TypeData/statistical analysis·DateNov 1, 2023

Agarose-based method shows potential in understanding extracellular vesicles' role in cancer metastasis

A collaborative study has developed an agarose spot migration assay to examine the ability of extracellular vesicles to attract other cells in a controlled environment. The assay revealed differences in EVs' recruitment capability for endothelial cells, particularly in highly metastatic cancer cells.

SourceGermans Trias i Pujol Research Institute·JournalBMC Biology·TypeExperimental study·DateOct 31, 2023

The world’s first collection of brain metastasis living samples will help treat each patient with the most effective therapy for them

A pioneering collection of brain metastasis living samples has been established, enabling researchers to study the response to specific drugs and identify the best therapeutic options for each patient. The RENACER network connects hospitals and patients, facilitating the rapid sharing of research findings and clinical trial data.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalTrends in Cancer·TypeNews article·DateOct 31, 2023

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·DateOct 22, 2023

More Aggressive treatment doesn’t impact quality of life for metastatic colorectal cancer patients, according to new study in JNCCN

A new study published in JNCCN found that intensive local-regional treatment to remove as much tumor as possible did not significantly impact overall quality of life for patients with metastatic colorectal cancer. However, the treatment was associated with a higher risk of adverse events.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeData/statistical analysis·DateOct 12, 2023